The DOI matches its Crossref record; 362 of the 362 references it cites were found in a registry or an index.
Doxorubicin‐Induced Cardiomyopathy in Children
Open accessAbstract
Doxorubicin‐induced cardiotoxicity in childhood cancer survivors is a growing problem. The population of patients at risk for cardiovascular disease is steadily increasing, as five‐year survival rates for all types of childhood cancers continue to improve. Doxorubicin affects the developing heart differently from the adult heart and in a subset of exposed patients, childhood exposure leads to late, irreversible cardiomyopathy. Notably, the prevalence of late‐onset toxicity is increasing in parallel with improved survival. By the year 2020, it is estimated that there will be 500,000 childhood cancer survivors and over 50,000 of them will suffer from doxorubicin‐induced cardiotoxicity. The majority of the research to‐date, concentrated on childhood cancer survivors, has focused mostly on clinical outcomes through well‐designed epidemiological and retrospective cohort studies. Preclinical studies have elucidated many of the cellular mechanisms that elicit acute toxicity in cardiomyocytes. However, more research is needed in the areas of early‐ and late‐onset cardiotoxicity and more importantly improving the scientific understanding of how other cells present in the cardiac milieu are impacted by doxorubicin exposure. The overall goal of this review is to succinctly summarize the major clinical and preclinical studies focused on doxorubicin‐induced cardiotoxicity. As the prevalence of patients affected by doxorubicin exposure continues to increase, it is imperative that the major gaps in existing research are identified and subsequently utilized to develop appropriate research priorities for the coming years. Well‐designed preclinical research models will enhance our understanding of the pathophysiology of doxorubicin‐induced cardiotoxicity and directly lead to better diagnosis, treatment, and prevention. © 2019 American Physiological Society.Compr Physiol 9:905‐931, 2019.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The cumulative anthracycline dose is a major risk factor for severe cardiomyopathy development but young age at treatment, female sex, peak drug exposure and additional stress to the heart have also been implicated 161,162,163 .”
From Osteosarcoma (2022) · cites this paper as [161]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Suliman, H. B., Carraway, M. S., Ali, A. S., Reynolds, C. M., Welty‐Wolf, K. E., & Piantadosi, C. A. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32967 · Cited by 261
Retracted2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · The Nephron journals/Nephron journals · doi:10.1159/000447068 · Cited by 11,782
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,868
Chronic Health Conditions in Adult Survivors of Childhood Cancer
Oeffinger, K. C., Mertens, A. C., Sklar, C. A., Kawashima, T. I., Hudson, M. M., Meadows, A. T., Friedman, D. L., Marina, N. M., Hobbie, W. L., Kadan‐Lottick, N. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa060185 · Cited by 3,597
Evidence for Cardiomyocyte Renewal in Humans
Bergmann, O., Bhardwaj, R. D., Bernard, S., Zdunek, S., Barnabé-Heider, F., Walsh, S., Zupicich, J., Alkass, K., Buchholz, B. A., Druid, H., et al. (2009) · Science · doi:10.1126/science.1164680 · Cited by 3,130
Physical Activity, All-Cause Mortality, and Longevity of College Alumni
Paffenbarger, R. S., Hyde, R., Wing, A. L., & Hsieh, C.-C. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603063141003 · Cited by 2,742
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
Hoff, D. D. V., LAYARD, M. W., BASA, P., DAVIS, H. L., HOFF, A. L. V., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,388
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–108 of 108
INCIDÊNCIA DE CÂNCER EM PESSOAS COM SÍNDROME DE DOWN: UM ESTUDO BIBLIOMÉTRICO
Cunha, T. F., Silva, A. O. D. C. E., Sampaio, C. E. P., Pinheiro, A. P. B., de Mello, L. R. G., Marins, A. L. C., dos Santos, R. O. M., Franco, A. S., de Paula, V. G., Neto, N. G. M. G., et al. (2024) · doi:10.22533/at.ed.4722410059
ABORDAGEM DOS CUIDADOS PALIATIVOS NO LINFOMA NÃO HODGKIN: UMA REVISÃO INTEGRATIVA
Franco, P. G., de Oliveira, R. J., Soares, S. S. S., Souza, N. V. D. D. O., Júnior, J. D. J. C., Peres, P. L. P., Varella, T. C. M. Y. M. L., Carvalho, E. C., Ramos, R. D. S., Santana, C., et al. (2024) · doi:10.22533/at.ed.4722410052
DIAGNÓSTICOS DE ENFERMAGEM RELACIONADOS ÀS MANIFESTAÇÕES CUTÂNEAS OCASIONADAS PELA RADIOTERAPIA
de Oliveira, A. F., de Morais, G. K. F., da Silva, S. F. A., Pimentel, N. B. L., de Paula, C. L., de Oliveira, A. M., Vieira, M. L. C., Leme, L. N. R., Júnior, E. F. P., de Oliveira, D. P. S., et al. (2024) · doi:10.22533/at.ed.4722410053
REPERCUSSÕES DO CÂNCER INFANTOJUVENIL: UMA REVISÃO INTEGRATIVA
de Abreu, L. R. S., Pinheiro, A. P. B., Soares, S. S. S., de Mello, L. R. G., Lisboa, C. D. D., Mazzoni, V. G., Henrique, D. D. M., Tomaz, A. P. K. D. A., & de Andrade, K. B. S. (2024) · doi:10.22533/at.ed.4722410058
Peculiarities of metabolic cardioprotection in children with anthracycline cardiomyopathy
Shatynska, T. V., Synoverska, О. B., Вовк, З. В., Berezna, T., & Shlimkevych, I. V. (2024) · Modern pediatrics Ukraine · doi:10.15574/sp.2024.139.54
REPERCUSSÕES DO CÂNCER INFANTOJUVENIL NA SAÚDE CARDIOVASCULAR DE SOBREVIVENTES
de Abreu, L. R. S., Soares, S. S. S., de Mello, L. R. G., Pinheiro, A. P. B., Carvalho, E. C., & de Andrade, K. B. S. (2025) · Revista Enfermagem Atual In Derme · doi:10.31011/reaid-2025-v.99-n.supl.1-art.2241
Hamledari, H., Jayousi, F., Shafaattalab, S., Dababneh, S., Geltink, R. I. K., Lange, P. F., Prondzynski, M., Tibbits, G. F., & Teves, S. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.14.676131
Interplay of oxidative stress and inflammatory mechanisms in doxorubicin-induced cardiomyopathy
Narasimhulu, C. A., Imaralu, O. E., Khan, M., & Singla, D. K. (2026) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00187.2026 · Cited by 1
Metadata
- Authors
- Mancilla, T. R., Iskra, B., & Aune, G. J.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- Aune, Gregory J.
- Venue
- Comprehensive Physiology
- Publisher
- Wiley
- Published
- 2019-06-12
- Volume
- 9
- Issue
- 3
- Pages
- 905-931
- ISSN
- 2040-4603 (ISSN-L)
- PMC
- PMC7000168
- OpenAlex
- W2953223155
- Cited by
- 108
- References
- 361
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 28 · 2023: 21 · 2022: 16 · 2021: 21 · 2020: 5 · 2019: 3
- Type
- other
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Comprehensive physiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (F30AG057213)
- National Institute of General Medical Sciences (T32GM113896)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- doxorubicin, cardiotoxicity, cardiomyopathy, childhood cancer survivors, cardiomyocytes, cardiac pathophysiology, childhood cancer, cardioprotection
- MeSH terms
- Age Factors, Antibiotics, Antineoplastic, Child, DNA Damage, Doxorubicin, Endothelium, Vascular, Humans, Mitochondria, Heart, Reactive Oxygen Species, Neuregulins, Myocytes, Cardiac, Cardiotoxicity, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
